Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$754.90 -1.38 (-0.18%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$752.50 -2.40 (-0.32%)
As of 09/12/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The current stock price is around $738, reflecting a strong market position and investor confidence.
  • The company reported impressive earnings, with a significant year-over-year revenue increase, indicating robust growth potential.
  • Eli Lilly and Co has a solid dividend payout ratio of approximately 39%, suggesting a commitment to returning value to shareholders.

Cons of Eli Lilly and Company

  • The stock has experienced fluctuations, with a notable 12-month high and low, indicating potential volatility.
  • Recent downgrades from some analysts may signal caution regarding the stock's short-term performance.
  • The company's high price-to-earnings (P/E) ratio suggests that the stock may be overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$715.79 billion
P/E Ratio
49.34
Consensus Rating
Moderate Buy
Consensus Price Target
$950.17 (+25.9% Upside)
Volume
2.20 million shares
Average Volume
3.74 million shares
Today's Range
$748.00
$761.60
50-Day Range
$625.15
$811.73
52-Week Range
$623.78
$942.35
Dividend Yield
0.79%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$178.10 -0.40 (-0.22%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$177.79 -0.31 (-0.17%)
As of 09/12/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The company recently reported a quarterly earnings per share (EPS) of $2.77, surpassing analyst expectations, which indicates strong financial performance and potential for growth.
  • Johnson & Johnson has a solid revenue stream, with a reported revenue of $23.74 billion for the quarter, reflecting a year-over-year increase of 5.8%, showcasing its resilience in the healthcare market.
  • The current stock price is around $177, which may present a favorable entry point for investors looking to capitalize on potential future growth.

Cons of Johnson & Johnson

  • The company experienced a slight decline in EPS compared to the previous year, which may raise concerns about its growth trajectory.
  • Insider selling activity has been noted, with an executive vice president selling over 56,000 shares, which could signal a lack of confidence in the stock's short-term performance.
  • Despite a strong revenue report, the company faces ongoing challenges in the healthcare sector, which could impact future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$429.89 billion
P/E Ratio
19.05
Consensus Rating
Moderate Buy
Consensus Price Target
$176.29 (-1.0% Downside)
Volume
7.22 million shares
Average Volume
7.55 million shares
Today's Range
$176.72
$178.80
50-Day Range
$155.23
$179.10
52-Week Range
$140.68
$181.16
Dividend Yield
2.91%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$218.40 -1.82 (-0.83%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$218.28 -0.13 (-0.06%)
As of 09/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • The current stock price is around $210, reflecting strong market interest and potential for growth.
  • Recent analyst upgrades have boosted target prices, indicating confidence in AbbVie's future performance.
  • AbbVie has a robust pipeline of pharmaceuticals, which could lead to increased revenues and market share.

Cons of AbbVie

  • Insider selling has been observed, with executives reducing their positions, which may signal concerns about the company's future.
  • The stock has a high P/E ratio, which could indicate that it is overvalued compared to its earnings.
  • AbbVie has a relatively low current ratio, suggesting potential liquidity issues in meeting short-term obligations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$389.03 billion
P/E Ratio
104.00
Consensus Rating
Moderate Buy
Consensus Price Target
$217.10 (-0.6% Downside)
Volume
4.42 million shares
Average Volume
4.35 million shares
Today's Range
$218.23
$220.38
50-Day Range
$184.77
$220.09
52-Week Range
$163.81
$221.76
Dividend Yield
2.98%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$352.61 -1.00 (-0.28%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$352.90 +0.29 (+0.08%)
As of 09/12/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The current stock price is around $317, reflecting a strong market capitalization of approximately $317.20 billion, indicating robust investor confidence.
  • UnitedHealth Group reported a year-over-year revenue increase of 12.9%, showcasing its growth potential and ability to expand its market share in the healthcare sector.
  • The company has a solid return on equity of 23.32%, which suggests effective management and a strong ability to generate profits from shareholders' investments.

Cons of UnitedHealth Group

  • The company recently missed earnings expectations, reporting $4.08 earnings per share compared to the consensus estimate of $4.45, which may raise concerns about its short-term performance.
  • UnitedHealth Group's price-to-earnings ratio of 15.17, while reasonable, may suggest that the stock is not undervalued, potentially limiting upside for new investors.
  • The firm has a debt-to-equity ratio of 0.73, indicating a moderate level of debt, which could pose risks if interest rates rise or if the company faces financial challenges.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$320.26 billion
P/E Ratio
15.28
Consensus Rating
Moderate Buy
Consensus Price Target
$358.95 (+1.8% Upside)
Volume
13.99 million shares
Average Volume
18.88 million shares
Today's Range
$352.46
$362.31
50-Day Range
$237.40
$353.89
52-Week Range
$234.60
$630.73
Dividend Yield
2.50%
Novartis stock logo

5. Novartis NYSE:NVS

$124.12 -3.58 (-2.80%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$123.70 -0.42 (-0.34%)
As of 09/12/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The current stock price is around $129.76, reflecting a strong market position and investor interest.
  • Recent earnings reports indicate a positive trend, with earnings per share surpassing analyst expectations, showcasing the company's robust financial health.
  • Analysts have recently upgraded their earnings estimates for FY2027, indicating confidence in the company's future profitability.

Cons of Novartis

  • Despite recent upgrades, the stock has experienced fluctuations, with a recent decline of about 1.3%, indicating potential volatility.
  • Some analysts have issued a "Sell" rating, reflecting concerns about the company's ability to maintain its growth trajectory amidst market challenges.
  • The company's debt-to-equity ratio stands at 0.53, which, while manageable, may raise concerns about financial leverage and risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$269.76 billion
P/E Ratio
18.07
Consensus Rating
Hold
Consensus Price Target
$120.33 (-3.1% Downside)
Volume
1.86 million shares
Average Volume
997,220 shares
Today's Range
$123.47
$125.14
50-Day Range
$113.55
$129.76
52-Week Range
$96.06
$130.46
Dividend Yield
2.03%
AstraZeneca stock logo

6. AstraZeneca NASDAQ:AZN

$79.56 -1.54 (-1.90%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$79.68 +0.13 (+0.16%)
As of 09/12/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • The current stock price is around $81, reflecting a strong market position and investor confidence.
  • AstraZeneca reported a quarterly revenue increase of 16.1% compared to the same quarter last year, indicating robust growth and demand for its products.
  • The company has a solid net margin of 14.68%, showcasing its ability to convert revenue into profit effectively.

Cons of AstraZeneca

  • The company recently cut its dividend, which may signal financial caution and could deter income-focused investors.
  • Despite strong revenue growth, the earnings per share (EPS) decreased from $1.24 to $1.09 year-over-year, indicating potential challenges in maintaining profitability.
  • The stock has a relatively high P/E ratio of 30.53, which may suggest that it is overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$251.52 billion
P/E Ratio
29.91
Consensus Rating
Moderate Buy
Consensus Price Target
$86.00 (+8.1% Upside)
Volume
4.49 million shares
Average Volume
3.17 million shares
Today's Range
$79.08
$81.16
50-Day Range
$68.72
$82.11
52-Week Range
$61.24
$82.41
Dividend Yield
1.25%
Novo Nordisk A/S stock logo

7. Novo Nordisk A/S NYSE:NVO

$54.94 +0.64 (+1.18%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$54.93 -0.01 (-0.02%)
As of 09/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $54, which may present a buying opportunity for investors looking for value.
  • Recent earnings reports show that Novo Nordisk has consistently exceeded earnings expectations, indicating strong financial performance.
  • The company has a high return on equity, suggesting effective management and profitability relative to shareholder equity.

Cons of Novo Nordisk A/S

  • The stock has experienced recent declines, with a drop of about 1.8% in mid-day trading, which may indicate volatility.
  • Some analysts have downgraded their ratings from "Buy" to "Hold," suggesting a cautious outlook on the stock's short-term performance.
  • The company has a relatively high price-to-earnings ratio compared to industry peers, which could indicate that the stock is overvalued.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$242.45 billion
P/E Ratio
15.09
Consensus Rating
Hold
Consensus Price Target
$81.00 (+47.4% Upside)
Volume
10.30 million shares
Average Volume
14.36 million shares
Today's Range
$54.33
$55.20
50-Day Range
$45.31
$71.67
52-Week Range
$45.05
$138.22
Dividend Yield
1.52%
Abbott Laboratories stock logo

8. Abbott Laboratories NYSE:ABT

$133.92 +1.27 (+0.96%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$134.08 +0.16 (+0.12%)
As of 09/12/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $134.55, which reflects a stable performance in the market.
  • Abbott Laboratories has demonstrated strong financial health with a quick ratio of 1.30 and a current ratio of 1.82, indicating good short-term liquidity and the ability to cover its liabilities.
  • The company reported a net margin of 32.43%, showcasing its efficiency in converting revenue into profit, which is attractive for investors looking for profitability.

Cons of Abbott Laboratories

  • The price-to-earnings (P/E) ratio of 16.21 may suggest that the stock is fairly valued, which could limit potential upside for investors seeking high-growth opportunities.
  • Abbott Laboratories has a beta of 0.69, indicating lower volatility compared to the market, which may not appeal to investors looking for high-risk, high-reward investments.
  • Insider ownership is relatively low at 0.46%, which could raise concerns about alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$230.87 billion
P/E Ratio
16.78
Consensus Rating
Moderate Buy
Consensus Price Target
$144.47 (+7.9% Upside)
Volume
5.70 million shares
Average Volume
4.67 million shares
Today's Range
$131.40
$134.96
50-Day Range
$120.76
$134.41
52-Week Range
$110.86
$141.23
Dividend Yield
1.78%
Merck & Co., Inc. stock logo

9. Merck & Co., Inc. NYSE:MRK

$82.87 -2.28 (-2.68%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$83.15 +0.28 (+0.34%)
As of 09/12/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $82, which is significantly lower than its 12-month high, indicating potential for price appreciation.
  • Merck has a strong return on equity of over 41%, suggesting effective management and profitability, which can lead to higher shareholder returns.
  • The company recently reported earnings per share that exceeded analyst expectations, demonstrating robust financial performance and resilience in the market.

Cons of Merck & Co., Inc.

  • Analysts have recently downgraded their price targets for Merck, indicating a cautious outlook on the stock's future performance.
  • The company’s revenue for the last quarter fell short of analyst expectations, which may raise concerns about future growth prospects.
  • Merck's PEG ratio is below 1, suggesting that the stock may not be undervalued relative to its growth rate, which could limit upside potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$212.69 billion
P/E Ratio
12.77
Consensus Rating
Hold
Consensus Price Target
$107.44 (+29.6% Upside)
Volume
9.93 million shares
Average Volume
11.15 million shares
Today's Range
$82.80
$85.18
50-Day Range
$78.17
$87.18
52-Week Range
$73.31
$119.38
Dividend Yield
3.81%
Thermo Fisher Scientific stock logo

10. Thermo Fisher Scientific NYSE:TMO

$479.48 -11.93 (-2.43%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$482.50 +3.02 (+0.63%)
As of 09/12/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $477, which may present a buying opportunity for investors looking for value in the life sciences sector.
  • Thermo Fisher Scientific Inc. has a strong market capitalization of approximately $180 billion, indicating a robust financial position and stability in the market.
  • Recent analyst ratings show a consensus of "Moderate Buy," with many analysts projecting positive growth and a price target significantly higher than the current stock price.

Cons of Thermo Fisher Scientific

  • Recent earnings estimates have been downgraded, indicating potential challenges in meeting growth expectations in the near term.
  • Insider selling activity has been noted, with significant shares sold by executives, which may raise concerns about the company's future performance.
  • The stock has experienced fluctuations, with a one-year high of $623.77 and a low of $385.46, suggesting volatility that could deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$185.56 billion
P/E Ratio
27.73
Consensus Rating
Moderate Buy
Consensus Price Target
$592.24 (+23.5% Upside)
Volume
1.54 million shares
Average Volume
1.56 million shares
Today's Range
$479.46
$491.26
50-Day Range
$405.15
$500.24
52-Week Range
$385.46
$623.77
Dividend Yield
0.35%
Intuitive Surgical stock logo

11. Intuitive Surgical NASDAQ:ISRG

$449.68 -6.17 (-1.35%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$451.00 +1.32 (+0.29%)
As of 09/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The current stock price is around $489, which is significantly lower than its 12-month high of $616, potentially offering a buying opportunity for investors looking for growth.
  • Intuitive Surgical, Inc. reported a strong quarterly earnings performance, with earnings per share (EPS) of $2.19, surpassing analyst expectations, indicating robust financial health and operational efficiency.
  • The company experienced a year-over-year revenue increase of 21.4%, showcasing its ability to grow and capture market share in the medical equipment sector.

Cons of Intuitive Surgical

  • The P/E ratio of 62.76 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Insider selling has been notable, with a total of 45,224 shares sold recently, which may raise concerns about the company's future prospects from those with inside knowledge.
  • The P/E/G ratio of 4.90 indicates that the stock's price is high relative to its growth rate, which could signal that the stock may not provide adequate returns for growth investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$163.41 billion
P/E Ratio
62.72
Consensus Rating
Moderate Buy
Consensus Price Target
$595.95 (+32.5% Upside)
Volume
2.22 million shares
Average Volume
2.11 million shares
Today's Range
$448.15
$454.15
50-Day Range
$441.18
$534.71
52-Week Range
$425.00
$616.00
Dividend Yield
N/A
Boston Scientific stock logo

12. Boston Scientific NYSE:BSX

$102.71 -1.63 (-1.56%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$103.00 +0.29 (+0.28%)
As of 09/12/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The company recently reported strong earnings, with earnings per share (EPS) of $0.75, exceeding analysts' expectations, indicating robust financial performance.
  • Boston Scientific Co. experienced a significant year-over-year revenue growth of approximately 22.8%, showcasing its expanding market presence and demand for its medical devices.
  • The current stock price is around $105, reflecting investor confidence and a stable valuation in the medical equipment sector.

Cons of Boston Scientific

  • Insider selling has been notable, with executives selling a significant number of shares recently, which could indicate a lack of confidence in the company's short-term performance.
  • The company has set its Q3 2025 EPS guidance lower than its recent performance, which may raise concerns about future growth potential.
  • Despite strong revenue growth, the medical device market is highly competitive, and any shifts in market dynamics could impact Boston Scientific Co.'s market share.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$154.61 billion
P/E Ratio
61.14
Consensus Rating
Buy
Consensus Price Target
$118.04 (+14.9% Upside)
Volume
10.54 million shares
Average Volume
6.12 million shares
Today's Range
$102.48
$104.43
50-Day Range
$102.44
$108.15
52-Week Range
$80.64
$109.50
Dividend Yield
N/A
Amgen stock logo

13. Amgen NASDAQ:AMGN

$276.39 -6.34 (-2.24%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$277.05 +0.66 (+0.24%)
As of 09/12/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $296.99, which may present a buying opportunity for investors looking for value in the biotechnology sector.
  • Amgen Inc. has a consensus rating of "Hold," indicating that analysts believe the stock is stable and may provide steady returns.
  • Insider ownership is at 0.76%, suggesting that company executives have a vested interest in the company's performance, which can align their goals with those of shareholders.

Cons of Amgen

  • The recent sale of shares by an insider, which represented a 14.95% decrease in their position, may raise concerns about the company's short-term outlook.
  • With a consensus target price of $304.43, the stock may not have significant upside potential in the near term, limiting potential gains for investors.
  • Amgen Inc. operates in a highly competitive biotechnology industry, which can lead to volatility in stock performance based on market conditions and regulatory changes.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$152.21 billion
P/E Ratio
22.60
Consensus Rating
Hold
Consensus Price Target
$304.43 (+10.1% Upside)
Volume
2.14 million shares
Average Volume
1.86 million shares
Today's Range
$276.07
$282.94
50-Day Range
$276.39
$309.22
52-Week Range
$253.30
$339.17
Dividend Yield
3.37%
Stryker stock logo

14. Stryker NYSE:SYK

$383.32 -5.47 (-1.41%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$383.37 +0.05 (+0.01%)
As of 09/12/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The company recently reported earnings per share (EPS) of $3.13, exceeding analyst expectations, which indicates strong financial performance and potential for growth.
  • Stryker Co. has shown a year-over-year revenue increase of 11.1%, suggesting robust demand for its medical technology products.
  • The current stock price is around $455, reflecting positive market sentiment and potential for further appreciation.

Cons of Stryker

  • The debt-to-equity ratio of 0.70 suggests that the company is somewhat reliant on debt financing, which could pose risks in a rising interest rate environment.
  • Despite recent growth, the medical technology sector can be highly competitive and subject to regulatory changes, which may impact future profitability.
  • Analysts have mixed ratings, with some maintaining a "hold" rating, indicating uncertainty about the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$148.64 billion
P/E Ratio
50.77
Consensus Rating
Moderate Buy
Consensus Price Target
$431.42 (+12.5% Upside)
Volume
985,297 shares
Average Volume
978,978 shares
Today's Range
$382.71
$387.80
50-Day Range
$374.93
$403.34
52-Week Range
$329.16
$406.19
Dividend Yield
0.86%
Gilead Sciences stock logo

15. Gilead Sciences NASDAQ:GILD

$114.55 -3.31 (-2.81%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$115.96 +1.41 (+1.23%)
As of 09/12/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The current stock price is around $115.25, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
  • Recent upgrades from multiple analysts, including a "buy" rating from Truist Financial and a target price increase to $127.00, indicate positive market sentiment and potential for stock appreciation.
  • Gilead Sciences, Inc. has a strong market capitalization of approximately $143 billion, suggesting stability and a solid foundation for future growth.

Cons of Gilead Sciences

  • Insiders have sold a significant number of shares recently, totaling 82,000 shares valued at over $9 million, which could raise concerns about the company's future performance.
  • The company has experienced a slight decline in stock value, down about 0.4%, which may indicate market volatility or investor uncertainty.
  • Despite recent upgrades, the consensus rating remains a "Moderate Buy," suggesting that not all analysts are fully confident in the stock's immediate prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$146.24 billion
P/E Ratio
22.82
Consensus Rating
Moderate Buy
Consensus Price Target
$115.39 (+0.7% Upside)
Volume
6.47 million shares
Average Volume
5.83 million shares
Today's Range
$114.18
$117.63
50-Day Range
$108.22
$120.47
52-Week Range
$81.57
$121.83
Dividend Yield
2.68%
Pfizer stock logo

16. Pfizer NYSE:PFE

$23.91 -0.95 (-3.82%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$23.96 +0.04 (+0.19%)
As of 09/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $24.59, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Pfizer Inc. recently reported strong quarterly earnings, with earnings per share (EPS) of $0.78, exceeding analysts' expectations, indicating robust financial performance.
  • The company has a solid revenue growth of 10.3% year-over-year, reflecting its ability to expand its market presence and product offerings.

Cons of Pfizer

  • The stock has a relatively high payout ratio of 91.49%, which may raise concerns about the sustainability of its dividend payments in the long term.
  • Despite recent earnings growth, the stock has been trading down about 0.5%, indicating potential volatility and market uncertainty.
  • Pfizer Inc. has a beta of 0.55, suggesting lower volatility compared to the market, but this may also indicate limited growth potential in a bullish market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$141.34 billion
P/E Ratio
12.72
Consensus Rating
Hold
Consensus Price Target
$28.12 (+17.6% Upside)
Volume
81.16 million shares
Average Volume
35.00 million shares
Today's Range
$23.84
$24.84
50-Day Range
$23.27
$25.83
52-Week Range
$20.92
$30.43
Dividend Yield
6.92%
Danaher stock logo

17. Danaher NYSE:DHR

$190.07 -5.09 (-2.61%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$190.33 +0.26 (+0.14%)
As of 09/12/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The company recently announced a quarterly dividend of $0.32 per share, which translates to an annualized dividend of $1.28. This provides a yield of approximately 0.7%, offering a return to shareholders.
  • Danaher Co. has a solid dividend payout ratio of 27.23%, indicating a balanced approach to returning profits to shareholders while retaining enough earnings for growth and reinvestment.
  • Recent insider transactions show that company insiders own 11.10% of the stock, which can be a positive indicator of confidence in the company's future performance.

Cons of Danaher

  • Despite the positive outlook, the stock has seen fluctuations, and the current price may not reflect long-term stability, which could deter risk-averse investors.
  • Insider selling, such as the recent transaction where a director sold 2,778 shares, could raise concerns about the company's short-term prospects or insider confidence.
  • The dividend yield of 0.7% is relatively low compared to other investment opportunities, which may not attract income-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$139.74 billion
P/E Ratio
40.44
Consensus Rating
Moderate Buy
Consensus Price Target
$246.35 (+29.6% Upside)
Volume
3.90 million shares
Average Volume
3.08 million shares
Today's Range
$188.86
$195.00
50-Day Range
$188.23
$212.24
52-Week Range
$171.00
$279.90
Dividend Yield
0.66%
Medtronic stock logo

18. Medtronic NYSE:MDT

$94.05 -0.20 (-0.21%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$94.46 +0.41 (+0.44%)
As of 09/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The current stock price is around $100, reflecting a positive outlook from analysts who have set price targets as high as $115.
  • Medtronic plc has a solid annualized dividend of $2.84, providing a dividend yield of 3.0%, which can be attractive for income-focused investors.
  • The company has a payout ratio of 78.24%, indicating a commitment to returning value to shareholders while still retaining enough earnings for growth.

Cons of Medtronic

  • The company's payout ratio of 78.24% may raise concerns about sustainability, as a high ratio can limit the funds available for reinvestment in growth opportunities.
  • Despite positive analyst ratings, the stock has faced volatility, which could pose risks for investors looking for stable returns.
  • Some analysts have issued neutral ratings, indicating that while the company is performing well, there may be limited upside potential in the near term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$120.89 billion
P/E Ratio
25.91
Consensus Rating
Moderate Buy
Consensus Price Target
$102.14 (+8.6% Upside)
Volume
7.33 million shares
Average Volume
6.89 million shares
Today's Range
$93.51
$95.29
50-Day Range
$87.73
$94.13
52-Week Range
$79.29
$96.25
Dividend Yield
3.01%
Sanofi stock logo

19. Sanofi NASDAQ:SNY

$47.03 -0.62 (-1.30%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$47.40 +0.37 (+0.78%)
As of 09/12/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • The current stock price is around $48.81, which may present a buying opportunity for investors looking for value.
  • Sanofi reported a strong revenue of $11.34 billion in its latest quarter, exceeding analyst expectations, indicating robust business performance.
  • The company has a solid net margin of 21.47%, suggesting effective cost management and profitability.

Cons of Sanofi

  • The company missed earnings per share (EPS) estimates in its latest report, which could raise concerns about future performance.
  • Sanofi's revenue decreased by 7.0% compared to the same quarter last year, indicating potential challenges in maintaining growth.
  • Despite a stable financial position, the stock's beta of 0.51 suggests lower volatility, which may not appeal to investors seeking high-growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$117.01 billion
P/E Ratio
11.31
Consensus Rating
Buy
Consensus Price Target
$62.67 (+33.2% Upside)
Volume
2.73 million shares
Average Volume
2.65 million shares
Today's Range
$47.01
$47.68
50-Day Range
$45.33
$51.35
52-Week Range
$44.73
$60.12
Dividend Yield
3.36%
Vertex Pharmaceuticals stock logo

20. Vertex Pharmaceuticals NASDAQ:VRTX

$394.53 -2.84 (-0.71%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$393.02 -1.51 (-0.38%)
As of 09/12/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The company recently reported earnings per share (EPS) of $4.52, surpassing analyst expectations, which indicates strong financial performance and potential for future growth.
  • Vertex Pharmaceuticals has shown a significant increase in revenue, with a reported $2.94 billion for the latest quarter, reflecting an 11.3% year-over-year growth, suggesting robust demand for its products.
  • The current stock price is around $389, which may present a buying opportunity for investors looking to enter at a lower price point compared to its 52-week high of $519.88.

Cons of Vertex Pharmaceuticals

  • The stock has experienced volatility, with a recent decline of about 1.8%, which may concern investors about short-term price fluctuations.
  • Analysts have mixed ratings on the stock, with some reducing their price targets, indicating uncertainty about future performance and potential market challenges.
  • Despite strong revenue growth, the company has a price-to-earnings ratio of 27.82, which may suggest that the stock is overvalued compared to its earnings, potentially limiting upside for new investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$101.88 billion
P/E Ratio
28.20
Consensus Rating
Moderate Buy
Consensus Price Target
$496.05 (+25.7% Upside)
Volume
978,279 shares
Average Volume
1.39 million shares
Today's Range
$393.17
$396.83
50-Day Range
$366.54
$479.53
52-Week Range
$362.50
$519.88
Dividend Yield
N/A
Bristol Myers Squibb stock logo

21. Bristol Myers Squibb NYSE:BMY

$46.22 -1.32 (-2.78%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$46.32 +0.09 (+0.21%)
As of 09/12/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The company reported strong quarterly earnings, exceeding analysts' expectations, which indicates robust financial health and operational efficiency.
  • Bristol-Myers Squibb has a diverse portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers and autoimmune diseases, which can drive future growth.
  • The current stock price is around $70, reflecting a solid position in the market and potential for appreciation as the company continues to innovate.

Cons of Bristol Myers Squibb

  • The company has a high dividend payout ratio of 100%, which may raise concerns about sustainability, especially if earnings fluctuate.
  • Recent revenue growth was modest, indicating potential challenges in maintaining momentum in a competitive biopharmaceutical market.
  • There are ongoing regulatory challenges and market pressures that could impact the approval and sales of new products.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$96.76 billion
P/E Ratio
18.64
Consensus Rating
Hold
Consensus Price Target
$56.38 (+22.0% Upside)
Volume
11.89 million shares
Average Volume
9.08 million shares
Today's Range
$46.19
$47.90
50-Day Range
$43.37
$48.99
52-Week Range
$42.96
$63.33
Dividend Yield
5.22%
CVS Health stock logo

22. CVS Health NYSE:CVS

$75.00 +0.33 (+0.44%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$74.84 -0.16 (-0.21%)
As of 09/12/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • The current stock price is around $66, which is significantly lower than its 52-week high of $75, indicating potential for price appreciation.
  • CVS Health Co. reported strong quarterly earnings, with earnings per share of $1.81, surpassing analyst expectations, which reflects robust financial performance.
  • The company has a solid market capitalization of approximately $94.74 billion, suggesting stability and a strong position in the healthcare sector.

Cons of CVS Health

  • The company has a relatively high debt-to-equity ratio of 0.74, which may indicate financial risk if not managed properly.
  • CVS Health Co. has a net margin of only 1.17%, suggesting that profitability could be a concern, especially in a competitive market.
  • Recent insider selling, including a director selling 7,500 shares, may raise concerns about the company's future prospects from those who are closely involved.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$94.71 billion
P/E Ratio
20.95
Consensus Rating
Moderate Buy
Consensus Price Target
$77.89 (+3.9% Upside)
Volume
6.40 million shares
Average Volume
6.90 million shares
Today's Range
$74.42
$75.55
50-Day Range
$58.82
$75.00
52-Week Range
$43.56
$75.55
Dividend Yield
3.56%
HCA Healthcare stock logo

23. HCA Healthcare NYSE:HCA

$405.54 +2.69 (+0.67%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$405.10 -0.44 (-0.11%)
As of 09/12/2025 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • HCA Healthcare, Inc. recently reported strong quarterly earnings, with earnings per share of $6.84, surpassing estimates and indicating robust financial performance.
  • The company has shown a year-over-year revenue increase of 6.4%, reflecting its growth potential in the healthcare sector.
  • HCA Healthcare, Inc. has set an optimistic guidance for fiscal year 2025, projecting earnings per share between 25.500 and 27.000, which suggests confidence in future profitability.

Cons of HCA Healthcare

  • HCA Healthcare, Inc. has a negative return on equity of over 7,363.11%, which may raise concerns about its efficiency in generating profits from shareholders' equity.
  • The company has a high debt-to-equity ratio of 69.07, indicating that it relies heavily on debt financing, which could pose risks in a rising interest rate environment.
  • Despite recent growth, the stock has experienced volatility, with fluctuations in trading volume and price, which may deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$94.26 billion
P/E Ratio
17.05
Consensus Rating
Moderate Buy
Consensus Price Target
$403.17 (-0.6% Downside)
Volume
761,184 shares
Average Volume
1.13 million shares
Today's Range
$399.64
$406.38
50-Day Range
$334.26
$420.68
52-Week Range
$289.98
$420.98
Dividend Yield
0.71%
McKesson stock logo

24. McKesson NYSE:MCK

$711.32 -8.48 (-1.18%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$714.50 +3.18 (+0.45%)
As of 09/12/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • McKesson Co. has received multiple positive ratings from analysts, with one analyst giving it a "Strong Buy" rating and several others issuing "Buy" ratings, indicating strong market confidence in the company's future performance.
  • The current stock price is around $687, which is significantly higher than its 1-year low of approximately $464, suggesting a strong recovery and potential for further growth.
  • Recent price target increases from analysts, such as Evercore ISI raising their target to $800, reflect optimism about the company's financial health and growth prospects.

Cons of McKesson

  • Insider selling has been observed, with significant shares sold by the CEO and other executives, which may raise concerns about their confidence in the company's future performance.
  • The stock has shown volatility, with a beta of 0.51, indicating that it may not be as stable as some investors prefer, especially in uncertain market conditions.
  • Despite positive ratings, the average target price from analysts is around $725.10, which is only slightly above the current stock price, suggesting limited upside potential in the near term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$89.53 billion
P/E Ratio
28.36
Consensus Rating
Moderate Buy
Consensus Price Target
$725.10 (+1.9% Upside)
Volume
522,385 shares
Average Volume
704,488 shares
Today's Range
$710.58
$724.00
50-Day Range
$658.78
$735.41
52-Week Range
$464.42
$737.89
Dividend Yield
0.46%
GSK stock logo

25. GSK NYSE:GSK

$40.81 -0.67 (-1.62%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$40.84 +0.02 (+0.06%)
As of 09/12/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $40.41, showing a recent increase, which may indicate positive market sentiment towards GSK plc.
  • GSK plc reported a strong quarterly earnings performance, with earnings per share (EPS) of $1.23, surpassing analysts' expectations, which reflects robust financial health.
  • The company has a solid revenue stream, reporting $10.64 billion for the quarter, significantly above analyst estimates, suggesting strong demand for its products.

Cons of GSK

  • The company has a relatively high debt-to-equity ratio of 1.07, which may indicate higher financial risk and could affect future growth potential.
  • GSK plc's dividend payout ratio is currently at 77.78%, which suggests that a significant portion of earnings is being distributed to shareholders, potentially limiting reinvestment in growth opportunities.
  • Despite recent positive earnings, the stock has an average rating of "Reduce" from analysts, indicating some caution regarding its future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$84.49 billion
P/E Ratio
18.89
Consensus Rating
Reduce
Consensus Price Target
$37.38 (-8.4% Downside)
Volume
4.74 million shares
Average Volume
3.55 million shares
Today's Range
$40.50
$41.39
50-Day Range
$36.21
$41.46
52-Week Range
$31.72
$43.62
Dividend Yield
4.06%
Cigna Group stock logo

26. Cigna Group NYSE:CI

$302.71 -3.16 (-1.03%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$303.50 +0.79 (+0.26%)
As of 09/12/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The Cigna Group recently reported strong earnings, with an EPS of $7.20, surpassing analyst expectations, indicating robust financial performance.
  • The company achieved a significant revenue increase of 11.0% year-over-year, reflecting its growth potential in the health services sector.
  • The current stock price is around $300, which may present a favorable entry point for investors looking for value in the health insurance market.

Cons of Cigna Group

  • The net margin of 1.92% is relatively low, which may raise concerns about the company's profitability compared to its peers.
  • Recent analyst ratings show mixed sentiments, with some firms downgrading their ratings, which could indicate uncertainty about future performance.
  • Insider transactions, such as the sale of 28,526 shares by an insider, may signal a lack of confidence in the stock's short-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$81.65 billion
P/E Ratio
16.52
Consensus Rating
Buy
Consensus Price Target
$374.76 (+23.8% Upside)
Volume
1.11 million shares
Average Volume
1.46 million shares
Today's Range
$302.61
$308.30
50-Day Range
$262.26
$313.34
52-Week Range
$256.89
$370.83
Dividend Yield
1.97%
Elevance Health stock logo

27. Elevance Health NYSE:ELV

$311.74 -3.15 (-1.00%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$313.00 +1.26 (+0.41%)
As of 09/12/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$70.91 billion
P/E Ratio
13.27
Consensus Rating
Moderate Buy
Consensus Price Target
$411.06 (+31.9% Upside)
Volume
1.50 million shares
Average Volume
2.08 million shares
Today's Range
$311.34
$319.24
50-Day Range
$274.10
$349.25
52-Week Range
$273.71
$559.95
Dividend Yield
2.17%
Zoetis stock logo

28. Zoetis NYSE:ZTS

$148.33 -2.28 (-1.51%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$147.88 -0.46 (-0.31%)
As of 09/12/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $149, which may present a buying opportunity for investors looking for value in the animal health sector.
  • Zoetis Inc. reported strong quarterly earnings, with earnings per share (EPS) of $1.76, exceeding analysts' expectations, indicating robust financial performance.
  • The company has shown a revenue increase of 4.2% compared to the same quarter last year, reflecting growth in its business operations.

Cons of Zoetis

  • Recent downgrades from analysts, including a reduction in price targets, may signal a lack of confidence in the stock's short-term performance.
  • The stock has experienced fluctuations, with a 52-week high of $200.33 and a low of $139.70, indicating potential volatility that could concern risk-averse investors.
  • Despite strong earnings, the company's P/E ratio of around 25.70 suggests that the stock may be overvalued compared to its earnings, which could deter some investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$66.75 billion
P/E Ratio
25.53
Consensus Rating
Moderate Buy
Consensus Price Target
$200.88 (+35.4% Upside)
Volume
3.11 million shares
Average Volume
2.28 million shares
Today's Range
$146.54
$150.05
50-Day Range
$145.76
$158.81
52-Week Range
$139.70
$200.33
Dividend Yield
1.33%
Alnylam Pharmaceuticals stock logo

29. Alnylam Pharmaceuticals NASDAQ:ALNY

$465.89 -2.69 (-0.57%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$470.00 +4.11 (+0.88%)
As of 09/12/2025 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • Alnylam Pharmaceuticals, Inc. has received a reaffirmed "Buy" rating from HC Wainwright, indicating strong confidence in the company's future performance.
  • The current stock price is around $452, which reflects a significant increase from its twelve-month low, suggesting positive market sentiment.
  • Analysts have set a target price of $570, indicating potential for substantial upside from the current trading levels.

Cons of Alnylam Pharmaceuticals

  • The company has a high debt-to-equity ratio, which may indicate financial risk and could affect its ability to invest in growth opportunities.
  • Insider ownership is relatively low at 1.20%, which may suggest a lack of alignment between management and shareholder interests.
  • Recent insider sales, including significant transactions by the CEO and a director, could raise concerns about the company's short-term outlook.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$61.42 billion
P/E Ratio
-188.62
Consensus Rating
Moderate Buy
Consensus Price Target
$421.28 (-9.6% Downside)
Volume
630,774 shares
Average Volume
1.11 million shares
Today's Range
$465.48
$475.69
50-Day Range
$311.12
$482.13
52-Week Range
$205.87
$484.21
Dividend Yield
N/A
Regeneron Pharmaceuticals stock logo

30. Regeneron Pharmaceuticals NASDAQ:REGN

$560.00 -8.20 (-1.44%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$559.75 -0.25 (-0.04%)
As of 09/12/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The company recently reported earnings per share significantly above analysts' expectations, indicating strong financial performance and potential for future growth.
  • Regeneron Pharmaceuticals, Inc. has a solid revenue growth of approximately 3.6% year-over-year, showcasing its ability to expand its market presence.
  • The current stock price is around $720, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.

Cons of Regeneron Pharmaceuticals

  • The stock has experienced volatility, with a 12-month high of $1,170.58 and a low of $476.49, which may indicate uncertainty in its market performance.
  • Despite recent earnings success, the company's P/E ratio of 14.32 suggests that it may be overvalued compared to its earnings, which could deter value-focused investors.
  • Regeneron Pharmaceuticals, Inc. operates in a highly competitive biopharmaceutical market, which could impact its market share and profitability in the long term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$60.22 billion
P/E Ratio
14.11
Consensus Rating
Moderate Buy
Consensus Price Target
$817.67 (+46.0% Upside)
Volume
602,540 shares
Average Volume
942,825 shares
Today's Range
$559.45
$570.00
50-Day Range
$538.11
$598.16
52-Week Range
$476.49
$1,170.58
Dividend Yield
0.62%
Cencora stock logo

31. Cencora NYSE:COR

$302.83 +0.03 (+0.01%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$302.48 -0.34 (-0.11%)
As of 09/12/2025 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is around $298.66, reflecting a recent increase, which may indicate positive market sentiment.
  • Cencora, Inc. reported strong quarterly earnings, with earnings per share (EPS) of $4.00, surpassing analyst expectations, which can signal robust financial health.
  • The company has shown a year-over-year revenue growth of 8.7%, suggesting a solid upward trend in business performance.

Cons of Cencora

  • Insider selling has occurred recently, with 34,125 shares sold, which may raise concerns about the confidence of insiders in the company's future.
  • The company has a relatively high debt-to-equity ratio of 3.64, indicating that it relies heavily on debt financing, which can be risky in volatile markets.
  • Despite recent growth, the net margin is only 0.60%, suggesting that profitability may be a concern compared to industry standards.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$58.71 billion
P/E Ratio
31.16
Consensus Rating
Moderate Buy
Consensus Price Target
$311.25 (+2.8% Upside)
Volume
1.19 million shares
Average Volume
1.31 million shares
Today's Range
$301.99
$307.51
50-Day Range
$278.18
$303.36
52-Week Range
$218.65
$309.35
Dividend Yield
0.73%
Becton, Dickinson and Company stock logo

32. Becton, Dickinson and Company NYSE:BDX

$187.22 -3.34 (-1.75%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$187.91 +0.69 (+0.37%)
As of 09/12/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The company reported earnings per share (EPS) of $3.68 for the latest quarter, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • Becton, Dickinson and Company has shown a year-over-year revenue increase of 10.4%, suggesting robust demand for its medical instruments and products.
  • The current stock price is around $211.44, which reflects a consensus rating of "Hold" from analysts, indicating stability and potential for future appreciation.

Cons of Becton, Dickinson and Company

  • The company's dividend payout ratio is currently at 74.82%, which may raise concerns about sustainability, especially if earnings do not continue to grow.
  • Some analysts have downgraded their ratings, reflecting mixed sentiments about the stock's future performance and potential volatility.
  • Despite recent revenue growth, the company operates in a highly competitive market, which could impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$54.62 billion
P/E Ratio
33.67
Consensus Rating
Hold
Consensus Price Target
$211.44 (+12.9% Upside)
Volume
1.12 million shares
Average Volume
1.75 million shares
Today's Range
$186.84
$189.90
50-Day Range
$172.50
$199.50
52-Week Range
$163.33
$251.99
Dividend Yield
2.18%
IDEXX Laboratories stock logo

33. IDEXX Laboratories NASDAQ:IDXX

$641.14 -4.02 (-0.62%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$644.06 +2.92 (+0.46%)
As of 09/12/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $652, reflecting a strong market position and investor confidence in the company's growth potential.
  • IDEXX Laboratories, Inc. reported a significant earnings per share of $3.63, surpassing analysts' expectations, indicating robust financial performance.
  • The company achieved a revenue of $1.11 billion in its latest quarter, showcasing a year-over-year growth of 10.6%, which suggests strong demand for its products.

Cons of IDEXX Laboratories

  • The stock has a relatively high price-to-earnings (P/E) ratio of around 54, which may indicate that it is overvalued compared to its earnings, posing a risk for potential investors.
  • Insider selling has been notable, with executives selling a significant number of shares recently, which could signal a lack of confidence in the company's short-term prospects.
  • Despite strong revenue growth, the company's quick ratio of 0.79 suggests potential liquidity concerns, indicating that it may struggle to meet short-term obligations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$51.62 billion
P/E Ratio
53.38
Consensus Rating
Moderate Buy
Consensus Price Target
$649.44 (+1.3% Upside)
Volume
317,919 shares
Average Volume
372,779 shares
Today's Range
$625.55
$644.86
50-Day Range
$514.61
$682.78
52-Week Range
$356.14
$688.12
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

34. Takeda Pharmaceutical NYSE:TAK

$15.11 -0.23 (-1.50%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$15.21 +0.10 (+0.66%)
As of 09/12/2025 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is approximately $15.45, reflecting a recent upward trend, which may indicate positive market sentiment towards the company.
  • Takeda Pharmaceutical Company Limited reported earnings per share of $0.52, exceeding analysts' expectations, which suggests strong financial performance and potential for future growth.
  • The company has a market capitalization of around $49 billion, indicating it is a significant player in the pharmaceutical industry, which can provide stability and investor confidence.

Cons of Takeda Pharmaceutical

  • The company has a net margin of only 3.20%, which may indicate challenges in profitability compared to competitors in the pharmaceutical sector.
  • Takeda's revenue for the latest quarter was $7.45 billion, falling short of analyst estimates, which could raise concerns about its growth trajectory.
  • Despite recent positive movements, the stock has shown volatility, with a beta of 0.22, indicating it may not respond strongly to market changes, which could limit potential gains.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$48.81 billion
P/E Ratio
50.37
Consensus Rating
Hold
Consensus Price Target
N/A
Volume
2.82 million shares
Average Volume
3.01 million shares
Today's Range
$15.03
$15.20
50-Day Range
$13.60
$15.50
52-Week Range
$12.80
$15.69
Dividend Yield
3.60%
argenex stock logo

35. argenex NASDAQ:ARGX

$756.38 -7.14 (-0.94%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$756.38 0.00 (0.00%)
As of 09/12/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The current stock price is around $5,900, reflecting strong investor interest and confidence in the company's growth potential.
  • argenx SE has a robust pipeline of therapies targeting various autoimmune diseases, with its lead product candidate, efgartigimod, showing promising results in clinical trials.
  • The company has demonstrated strong financial performance, with a return on equity of over 21%, indicating effective management and profitability.

Cons of argenex

  • Despite its promising pipeline, the biotechnology sector is highly volatile, and the success of drug development is uncertain, which can lead to significant stock price fluctuations.
  • High dependency on the success of a few key products may pose risks; if efgartigimod or other candidates fail to gain regulatory approval, it could adversely affect the company's valuation.
  • Market competition in the biotechnology field is fierce, with many companies vying for the same therapeutic areas, which could impact argenx SE's market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$46.73 billion
P/E Ratio
38.79
Consensus Rating
Buy
Consensus Price Target
$772.84 (+2.2% Upside)
Volume
339,273 shares
Average Volume
354,777 shares
Today's Range
$752.05
$767.97
50-Day Range
$538.64
$768.00
52-Week Range
$510.05
$779.03
Dividend Yield
N/A
Veeva Systems stock logo

36. Veeva Systems NYSE:VEEV

$276.21 -3.26 (-1.17%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$275.85 -0.36 (-0.13%)
As of 09/12/2025 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The stock has a consensus rating of "Moderate Buy" from analysts, indicating positive sentiment towards its future performance.
  • Recent price targets from various analysts suggest significant upside potential, with targets ranging from $310.00 to $355.00, reflecting confidence in the company's growth.
  • The current stock price is around $296, which is close to its 1-year high, suggesting strong market performance and investor interest.

Cons of Veeva Systems

  • Some analysts have issued Hold or Sell ratings, indicating that not all market experts are confident in the stock's future performance.
  • Insider selling activity has been noted, with insiders selling over 1,000 shares recently, which could signal a lack of confidence in the stock's short-term prospects.
  • The stock has experienced fluctuations, with a 1-year low of $200.30, indicating potential volatility that could concern risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.81 billion
P/E Ratio
56.72
Consensus Rating
Moderate Buy
Consensus Price Target
$301.48 (+9.1% Upside)
Volume
935,743 shares
Average Volume
1.48 million shares
Today's Range
$273.49
$280.65
50-Day Range
$268.85
$295.23
52-Week Range
$200.30
$296.72
Dividend Yield
N/A
Edwards Lifesciences stock logo

37. Edwards Lifesciences NYSE:EW

$77.50 -0.51 (-0.65%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$77.47 -0.03 (-0.03%)
As of 09/12/2025 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • Recent upgrades from multiple analysts, including a boost to a "strong-buy" rating, indicate strong confidence in the company's future performance.
  • The current stock price is around $78.62, which may present a buying opportunity for investors looking for growth in the healthcare sector.
  • Analysts have set a consensus price target of approximately $85.90, suggesting potential upside from the current price.

Cons of Edwards Lifesciences

  • Insider selling activity has been noted, with significant shares sold recently, which may raise concerns about the company's future prospects.
  • The stock has experienced fluctuations, with a recent trading down of about 1.5%, indicating potential volatility in the short term.
  • Despite positive ratings, there is still one "sell" rating among analysts, suggesting that not all market participants are confident in the stock's performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.80 billion
P/E Ratio
11.15
Consensus Rating
Moderate Buy
Consensus Price Target
$86.26 (+11.3% Upside)
Volume
6.30 million shares
Average Volume
3.60 million shares
Today's Range
$76.49
$77.82
50-Day Range
$75.68
$81.76
52-Week Range
$64.00
$83.00
Dividend Yield
N/A
Haleon stock logo

38. Haleon NYSE:HLN

$9.80 -0.07 (-0.66%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$9.80 0.00 (0.00%)
As of 09/12/2025 05:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • Haleon plc recently increased its semi-annual dividend to $0.0555 per share, reflecting a commitment to returning value to shareholders. This increase from the previous dividend indicates strong financial health and a positive outlook.
  • The current stock price is around $12.33, which aligns with analysts' consensus ratings of "Moderate Buy," suggesting potential for growth in the near future.
  • Institutional investors have shown confidence in Haleon plc, with significant increases in holdings by firms such as Hanson & Doremus Investment Management and Bartlett & CO. Wealth Management LLC, indicating strong institutional support.

Cons of Haleon

  • Despite the positive dividend increase, the payout ratio stands at 28.21%, which, while sustainable, may limit the company's ability to reinvest in growth opportunities.
  • Some analysts have downgraded Haleon plc's stock rating to "Hold," indicating that there may be concerns about the stock's short-term performance and potential volatility.
  • Only 6.67% of the stock is owned by hedge funds and other institutional investors, which may suggest a lack of broader institutional confidence compared to other companies in the sector.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.20 billion
P/E Ratio
25.14
Consensus Rating
Moderate Buy
Consensus Price Target
$12.33 (+25.7% Upside)
Volume
7.83 million shares
Average Volume
7.79 million shares
Today's Range
$9.79
$9.92
50-Day Range
$9.28
$10.16
52-Week Range
$8.86
$11.42
Dividend Yield
1.13%
ResMed stock logo

39. ResMed NYSE:RMD

$270.67 -3.94 (-1.44%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$278.10 +7.43 (+2.74%)
As of 09/12/2025 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • ResMed Inc. recently reported strong quarterly earnings, exceeding analysts' expectations with earnings per share of $2.55, indicating robust financial health and operational efficiency.
  • The company has shown a significant year-over-year revenue growth of over 10%, reflecting its ability to expand its market presence and increase sales.
  • ResMed Inc. has increased its quarterly dividend to $0.60 per share, which represents a positive change from the previous dividend, signaling confidence in its ongoing profitability and commitment to returning value to shareholders.

Cons of ResMed

  • Insider selling has been observed, with significant shares sold by both the Director and CEO, which may raise concerns about the company's future prospects and insider confidence.
  • The dividend payout ratio is approximately 25.24%, which, while sustainable, indicates that a significant portion of earnings is retained for reinvestment rather than distributed to shareholders.
  • Corporate insiders own only 0.71% of the company's stock, suggesting limited alignment between management and shareholder interests, which could impact decision-making.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.21 billion
P/E Ratio
28.46
Consensus Rating
Moderate Buy
Consensus Price Target
$278.36 (+2.8% Upside)
Volume
1.26 million shares
Average Volume
925,531 shares
Today's Range
$269.00
$273.56
50-Day Range
$251.98
$293.48
52-Week Range
$199.92
$293.81
Dividend Yield
0.87%
Alcon stock logo

40. Alcon NYSE:ALC

$78.32 -1.36 (-1.71%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$78.29 -0.03 (-0.04%)
As of 09/12/2025 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $91.50, reflecting a strong performance in the market.
  • Alcon Inc. has shown a positive fifty-two week performance, indicating a growth trend that may attract investors.
  • Institutional ownership is significant, suggesting confidence from large investors in the company's future prospects.

Cons of Alcon

  • Despite a positive performance, the average daily volume has decreased, which may indicate reduced trading interest.
  • The company has experienced fluctuations in shares shorted, which could suggest volatility and uncertainty in investor confidence.
  • With a relatively high number of outstanding shares, any negative news could impact the stock price significantly.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.30 billion
P/E Ratio
36.43
Consensus Rating
Moderate Buy
Consensus Price Target
$96.06 (+22.6% Upside)
Volume
1.31 million shares
Average Volume
2.49 million shares
Today's Range
$78.28
$79.04
50-Day Range
$77.85
$92.25
52-Week Range
$77.44
$100.71
Dividend Yield
N/A
BeOne Medicines stock logo

41. BeOne Medicines NASDAQ:ONC

$324.34 -11.33 (-3.38%)
As of 09/12/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$36.79 billion
P/E Ratio
-187.48
Consensus Rating
Buy
Consensus Price Target
$330.89 (+2.0% Upside)
Volume
274,640 shares
Average Volume
351,780 shares
Today's Range
$324.03
$333.03
50-Day Range
$240.99
$351.13
52-Week Range
$170.99
$351.27
Dividend Yield
N/A
Cardinal Health stock logo

42. Cardinal Health NYSE:CAH

$152.34 -0.14 (-0.09%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$152.50 +0.16 (+0.11%)
As of 09/12/2025 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The current stock price is around $148.82, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Cardinal Health, Inc. has a solid annualized dividend of $2.04, translating to a dividend yield of 1.4%, providing a steady income stream for investors.
  • The company maintains a low payout ratio of 31.63%, indicating that it retains a significant portion of its earnings for growth and reinvestment, which can be a positive sign for long-term investors.

Cons of Cardinal Health

  • Insider sales have totaled 271,676 shares worth over $40 million in the last three months, which could raise concerns about the company's future performance and insider confidence.
  • The company has experienced a significant decrease in insider ownership, with the CEO's stake dropping by 61.45%, which may signal potential issues within the company.
  • Despite a strong institutional presence, the low percentage of stock owned by insiders (0.09%) may indicate a lack of alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.41 billion
P/E Ratio
23.62
Consensus Rating
Moderate Buy
Consensus Price Target
$165.93 (+8.9% Upside)
Volume
1.16 million shares
Average Volume
2.18 million shares
Today's Range
$151.83
$153.89
50-Day Range
$146.18
$167.62
52-Week Range
$106.54
$168.44
Dividend Yield
1.34%
Agilent Technologies stock logo

43. Agilent Technologies NYSE:A

$123.19 -3.54 (-2.79%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$123.22 +0.03 (+0.03%)
As of 09/12/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The current stock price is around $128, reflecting a stable performance in the market.
  • Agilent Technologies, Inc. reported a revenue increase of over 10% compared to the same quarter last year, indicating strong growth potential.
  • The company has a solid market capitalization of approximately $36 billion, suggesting a robust financial position.

Cons of Agilent Technologies

  • Some analysts have downgraded their price targets, with UBS Group lowering theirs from $150 to $130, which may indicate concerns about future performance.
  • The stock has shown volatility, with a 12-month high of $153.84 and a low of $96.43, suggesting potential risks for investors.
  • The price-to-earnings ratio is around 30, which may be considered high, indicating that the stock could be overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.93 billion
P/E Ratio
28.92
Consensus Rating
Moderate Buy
Consensus Price Target
$139.25 (+13.0% Upside)
Volume
1.25 million shares
Average Volume
1.69 million shares
Today's Range
$123.13
$126.53
50-Day Range
$112.12
$128.69
52-Week Range
$96.43
$153.84
Dividend Yield
0.78%
GE HealthCare Technologies stock logo

44. GE HealthCare Technologies NASDAQ:GEHC

$76.44 -1.52 (-1.95%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$76.71 +0.27 (+0.35%)
As of 09/12/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The current stock price is around $74, which is significantly lower than its 52-week high of $94.80, indicating potential for price appreciation.
  • The company reported a strong earnings per share (EPS) of $1.06 for the latest quarter, surpassing analysts' expectations, which reflects robust financial performance.
  • GE HealthCare Technologies Inc. has a solid return on equity of 23.93%, indicating effective management and profitability relative to shareholder equity.

Cons of GE HealthCare Technologies

  • The company has a debt-to-equity ratio of 0.85, which, while manageable, indicates that it has a significant amount of debt compared to equity, potentially increasing financial risk.
  • The PEG ratio of 3.01 suggests that the stock may be overvalued relative to its earnings growth, which could deter value-focused investors.
  • Despite a positive revenue growth of 3.5% year-over-year, the growth rate may not be sufficient to attract aggressive growth investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.59 billion
P/E Ratio
15.66
Consensus Rating
Moderate Buy
Consensus Price Target
$88.40 (+15.6% Upside)
Volume
3.25 million shares
Average Volume
2.95 million shares
Today's Range
$76.38
$77.64
50-Day Range
$69.85
$78.71
52-Week Range
$57.65
$94.80
Dividend Yield
0.18%
Humana stock logo

45. Humana NYSE:HUM

$276.36 -2.36 (-0.85%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$274.50 -1.86 (-0.67%)
As of 09/12/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $308, reflecting a strong market presence and potential for appreciation.
  • Humana Inc. has demonstrated solid revenue growth, with a year-over-year increase of approximately 9.6%, indicating a robust business model.
  • The company has a relatively low beta of 0.44, suggesting that its stock is less volatile compared to the market, which may appeal to risk-averse investors.

Cons of Humana

  • The company reported earnings per share of $6.27, which was below the consensus estimate, raising concerns about its short-term profitability.
  • Humana Inc. has a price-to-earnings (P/E) ratio of around 23.80, which may be considered high compared to industry averages, suggesting that the stock could be overvalued.
  • With a net margin of only 1.28%, the company may face challenges in maintaining profitability amidst rising operational costs.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.52 billion
P/E Ratio
21.21
Consensus Rating
Hold
Consensus Price Target
$289.24 (+4.7% Upside)
Volume
1.14 million shares
Average Volume
1.65 million shares
Today's Range
$274.20
$279.94
50-Day Range
$220.08
$312.22
52-Week Range
$206.87
$325.75
Dividend Yield
1.29%
IQVIA stock logo

46. IQVIA NYSE:IQV

$187.34 -3.35 (-1.76%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$186.63 -0.71 (-0.38%)
As of 09/12/2025 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The current stock price is around $191, reflecting a strong market position and investor interest in the company's services.
  • IQVIA Holdings Inc. provides advanced analytics and technology solutions, which are increasingly in demand in the life sciences industry, indicating potential for growth.
  • Recent insider transactions show confidence from company executives, as they continue to hold significant shares even after selling portions of their holdings.

Cons of IQVIA

  • Insider sales, such as those by Keriann Cherofsky and Eric Sherbet, may raise concerns about the company's future performance and could indicate a lack of confidence among executives.
  • Insiders own only 1.60% of the company's stock, which may suggest limited alignment between management and shareholder interests.
  • The recent decrease in insider ownership percentages could signal potential volatility in stock performance, which may deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.42 billion
P/E Ratio
27.11
Consensus Rating
Moderate Buy
Consensus Price Target
$229.64 (+22.6% Upside)
Volume
946,284 shares
Average Volume
1.14 million shares
Today's Range
$186.47
$190.28
50-Day Range
$157.71
$201.06
52-Week Range
$134.65
$248.03
Dividend Yield
N/A
Insmed stock logo

47. Insmed NASDAQ:INSM

$145.93 +0.14 (+0.10%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$145.25 -0.68 (-0.47%)
As of 09/12/2025 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Market Capitalization
$30.82 billion
P/E Ratio
-25.56
Consensus Rating
Moderate Buy
Consensus Price Target
$139.86 (-4.2% Downside)
Volume
1.93 million shares
Average Volume
2.21 million shares
Today's Range
$144.00
$148.22
50-Day Range
$96.14
$147.20
52-Week Range
$60.40
$149.08
Dividend Yield
N/A
DexCom stock logo

48. DexCom NASDAQ:DXCM

$76.22 +0.22 (+0.29%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$75.95 -0.27 (-0.35%)
As of 09/12/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • The current stock price is around $80, which reflects a strong performance in the medical device sector, particularly in continuous glucose monitoring systems.
  • DexCom, Inc. reported a significant year-over-year revenue increase of 15.2%, indicating robust growth and demand for its products.
  • The company has a high return on equity of over 30%, suggesting effective management and profitability, which can be attractive to investors looking for strong financial performance.

Cons of DexCom

  • The price-to-earnings (P/E) ratio is around 56, which may suggest that the stock is overvalued compared to its earnings, potentially leading to a correction.
  • Insider selling activity has been noted, with executives selling shares, which could indicate a lack of confidence in the stock's short-term performance.
  • The stock has a beta of 1.48, indicating higher volatility compared to the market, which may pose risks for conservative investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.80 billion
P/E Ratio
52.93
Consensus Rating
Moderate Buy
Consensus Price Target
$99.89 (+31.1% Upside)
Volume
3.05 million shares
Average Volume
3.99 million shares
Today's Range
$75.39
$76.69
50-Day Range
$74.30
$89.53
52-Week Range
$57.52
$93.25
Dividend Yield
N/A
Koninklijke Philips stock logo

49. Koninklijke Philips NYSE:PHG

$28.22 -0.40 (-1.40%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$28.12 -0.09 (-0.34%)
As of 09/12/2025 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. More about Koninklijke Philips

Pros of Koninklijke Philips

  • The current stock price is around $27.27, showing a recent upward trend, which may indicate positive market sentiment.
  • Recent earnings reports have exceeded analysts' expectations, with significant revenue growth, suggesting strong operational performance.
  • Institutional interest is growing, with several hedge funds increasing their stakes, indicating confidence in the company's future prospects.

Cons of Koninklijke Philips

  • The company has a relatively high price-to-earnings (P/E) ratio, which may suggest that the stock is overvalued compared to its earnings.
  • Recent downgrades from analysts, including a shift from "buy" to "hold," could indicate concerns about future performance.
  • Market volatility and economic uncertainties could impact the company's growth and profitability in the near term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$27.56 billion
P/E Ratio
148.53
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
491,670 shares
Average Volume
682,512 shares
Today's Range
$28.11
$28.37
50-Day Range
$23.84
$28.63
52-Week Range
$21.48
$32.91
Dividend Yield
2.87%
Mettler-Toledo International stock logo

50. Mettler-Toledo International NYSE:MTD

$1,258.06 -24.66 (-1.92%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$1,246.00 -12.06 (-0.96%)
As of 09/12/2025 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. More about Mettler-Toledo International

Pros of Mettler-Toledo International

  • The current stock price is around $1,308, reflecting strong market confidence in the company's performance and growth potential.
  • Mettler-Toledo International Inc. operates in diverse segments, including U.S., Swiss, Western European, and Chinese operations, which helps mitigate risks associated with economic fluctuations in any single region.
  • Recent insider trading activity indicates confidence among executives, with significant stock sales suggesting they believe the stock is at a favorable price point.

Cons of Mettler-Toledo International

  • Recent insider sales have resulted in a notable decrease in their ownership positions, which could signal a lack of confidence in the stock's future performance.
  • The company has seen a significant percentage of insider ownership decrease, which may raise concerns about the alignment of interests between management and shareholders.
  • Market volatility can impact the stock price, and recent fluctuations may deter risk-averse investors from committing to Mettler-Toledo International Inc.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$26.42 billion
P/E Ratio
31.86
Consensus Rating
Moderate Buy
Consensus Price Target
$1,311.11 (+4.2% Upside)
Volume
109,047 shares
Average Volume
119,443 shares
Today's Range
$1,255.22
$1,279.42
50-Day Range
$1,165.30
$1,324.30
52-Week Range
$946.69
$1,521.01
Dividend Yield
N/A